🚀 VC round data is live in beta, check it out!
Duopharma Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Duopharma Biotech and similar public comparables like Avacta Group, Aura Biosciences, Neurogene, Atea Pharmaceuticals and more.
Duopharma Biotech Overview
About Duopharma Biotech
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
Founded
2000
HQ
Employees
2.0K
Website
Sectors
Financials (LTM)
EV
$420M
Duopharma Biotech Financials
Duopharma Biotech reported last 12-month revenue of $240M and EBITDA of $47M.
In the same LTM period, Duopharma Biotech generated $47M in EBITDA and $23M in net income.
Revenue (LTM)
Duopharma Biotech P&L
In the most recent fiscal year, Duopharma Biotech reported revenue of $238M and EBITDA of $47M.
Duopharma Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $240M | XXX | $238M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $93M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $47M | XXX | $47M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $23M | XXX | $22M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $52M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Duopharma Biotech Stock Performance
Duopharma Biotech has current market cap of $363M, and enterprise value of $420M.
Market Cap Evolution
Duopharma Biotech's stock price is $0.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $420M | $363M | 0.1% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDuopharma Biotech Valuation Multiples
Duopharma Biotech trades at 1.7x EV/Revenue multiple, and 9.0x EV/EBITDA.
EV / Revenue (LTM)
Duopharma Biotech Financial Valuation Multiples
As of March 19, 2026, Duopharma Biotech has market cap of $363M and EV of $420M.
Equity research analysts estimate Duopharma Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Duopharma Biotech has a P/E ratio of 15.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $363M | XXX | $363M | XXX | XXX | XXX |
| EV (current) | $420M | XXX | $420M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 8.9x | XXX | XXX | XXX |
| EV/EBIT | 12.1x | XXX | 12.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.5x | XXX | XXX | XXX |
| P/E | 15.6x | XXX | 16.2x | XXX | XXX | XXX |
| EV/FCF | 88.7x | XXX | 22.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Duopharma Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Duopharma Biotech Margins & Growth Rates
Duopharma Biotech's revenue in the last 12 month grew by 7%.
Duopharma Biotech's revenue per employee in the last FY averaged $0.1M.
Duopharma Biotech's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Duopharma Biotech's rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Duopharma Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Duopharma Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Aura Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Atea Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Duopharma Biotech M&A Activity
Duopharma Biotech acquired XXX companies to date.
Last acquisition by Duopharma Biotech was on XXXXXXXX, XXXXX. Duopharma Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Duopharma Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDuopharma Biotech Investment Activity
Duopharma Biotech invested in XXX companies to date.
Duopharma Biotech made its latest investment on XXXXXXXX, XXXXX. Duopharma Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Duopharma Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Duopharma Biotech
| When was Duopharma Biotech founded? | Duopharma Biotech was founded in 2000. |
| Where is Duopharma Biotech headquartered? | Duopharma Biotech is headquartered in Malaysia. |
| How many employees does Duopharma Biotech have? | As of today, Duopharma Biotech has over 2K employees. |
| Is Duopharma Biotech publicly listed? | Yes, Duopharma Biotech is a public company listed on Bursa Malaysia. |
| What is the stock symbol of Duopharma Biotech? | Duopharma Biotech trades under 7148 ticker. |
| When did Duopharma Biotech go public? | Duopharma Biotech went public in 2002. |
| Who are competitors of Duopharma Biotech? | Duopharma Biotech main competitors are Avacta Group, Aura Biosciences, Neurogene, Atea Pharmaceuticals. |
| What is the current market cap of Duopharma Biotech? | Duopharma Biotech's current market cap is $363M. |
| What is the current revenue of Duopharma Biotech? | Duopharma Biotech's last 12 months revenue is $240M. |
| What is the current revenue growth of Duopharma Biotech? | Duopharma Biotech revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Duopharma Biotech? | Current revenue multiple of Duopharma Biotech is 1.7x. |
| Is Duopharma Biotech profitable? | Yes, Duopharma Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Duopharma Biotech? | Duopharma Biotech's last 12 months EBITDA is $47M. |
| What is Duopharma Biotech's EBITDA margin? | Duopharma Biotech's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Duopharma Biotech? | Current EBITDA multiple of Duopharma Biotech is 9.0x. |
| What is the current FCF of Duopharma Biotech? | Duopharma Biotech's last 12 months FCF is $5M. |
| What is Duopharma Biotech's FCF margin? | Duopharma Biotech's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Duopharma Biotech? | Current FCF multiple of Duopharma Biotech is 88.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.